Watch CMMB. Know when insiders buy.
One email the day a filing lands. Free.
Work order
75
PASS · insiders 50, shorts 100
Insiders, 90 days
−$7K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.6BP/E 150.6DIV YIELD —FCF YIELD -0.71%REV TTM —NET INCOME −$9MNET CASH —52W 1.36 – 3.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2023 · Mar 31 | — | — | — | — | −$8.8M | — | 0.04 | −$7.2M | $1K | −$7.2M | May 11 |
| Q4 2022 · Dec 31derived | — | — | — | — | −$8.3M | — | 0.04 | −$5.7M | $1K | −$5.7M | Apr 4 |
| Q3 2022 · Sep 30 | — | — | — | — | −$8.1M | — | 0.04 | −$5.3M | $42K | −$5.3M | Nov 10 |
| Q2 2022 · Jun 30 | — | — | — | — | −$6.2M | — | 0.03 | −$5.7M | $11K | −$5.7M | Nov 10 |
| Q1 2022 · Mar 31 | — | — | — | — | −$5.1M | — | 0.02 | −$3.7M | $14K | −$3.7M | May 11 |
| Q4 2021 · Dec 31derived | — | — | — | — | −$5M | — | 0.02 | −$2.9M | $134K | −$3M | Mar 28 |
| Q3 2021 · Sep 30 | — | — | — | — | −$3M | — | 0.01 | −$2.6M | $0 | −$2.6M | Nov 10 |
| Q2 2021 · Jun 30 | — | — | — | — | −$2.8M | — | 0.01 | −$5.6M | $102K | −$5.7M | Nov 10 |
| Q1 2021 · Mar 31 | — | — | — | — | −$1.7M | — | 0.01 | −$1.3M | $3K | −$1.3M | Nov 10 |
| Q4 2020 · Dec 31derived | — | — | — | — | −$2M | — | 0.01 | −$1.6M | $1K | −$1.6M | Mar 30 |
| Q3 2020 · Sep 30 | — | — | — | — | −$1.2M | — | 0.01 | −$901K | $20K | −$921K | Nov 12 |
| Q2 2020 · Jun 30 | — | — | — | — | −$1.1M | — | 0.01 | −$873K | $7K | −$880K | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$112M | −$9M | — | 0.02 | −$11.1M | $3K | −$11.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$103M | −$13.9M | — | 0.04 | −$15.4M | $0 | −$15.4M | — | — |
| FY2023 · to Dec 31 | — | — | — | −$24.2M | — | 0.10 | −$23.6M | $3K | −$23.6M | — | — |
| FY2022 · to Dec 31 | — | — | — | −$27.6M | — | 0.12 | −$20.4M | $68K | −$20.4M | — | — |
| FY2021 · to Dec 31 | — | — | — | −$12.5M | — | 0.06 | −$12.4M | $239K | −$12.6M | — | — |
| FY2020 · to Dec 31 | — | — | — | −$6M | — | 0.04 | −$5.2M | $38K | −$5.3M | — | — |
Every number comes from Chemomab Therapeutics Ltd.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.